Feasibility study of Epirubicin-Eluting-Bead Embolization for Hepatocellular Carcinoma (JIVROSG-1301)

Not Applicable

• Conditions: Hepatocellular carcinoma

• Registration Number: JPRN-UMIN000013771
• Lead Sponsor: Japan Interventional Radiology In Oncology Study Group(IVROSG)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-04-23
• Study Completion: 2014-09-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

Not provided

Exclusion Criteria

1) Prior surgical reconstruction or endoscopic treatment of the biliary tract 2) Clinically significant refractory ascites or pleural effusion 3) Severe arterio-portal or arterio-venous shunts in the liver 4) Allergy to contrast medium that precludes angiography 5) Severe, active co-morbidity, defined as follows: - Uncontrolled cardiac failure, angina and/or rhythm disorders - Myocardial infarction within the last 6 months - Renal failure - Active infection (viral hepatitis is allowed) - Active gastrointestinal bleeding - Other active malignant tumor - Hepatic encephalopathy or severe mental disorder 6) Pregnancy, nursing women, or women of childbearing potential, and men who are sexually active and not willing or able to use medically acceptable forms of contraception 7) Not eligible because of safety issues judged by investigators

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Response rate

Secondary Outcome Measures

Name	Time	Method
Adverse events